Safety and efficacy of Hansenula-derived PEGylated-interferon alpha-2a and ribavirin combination in chronic hepatitis C Egyptian children

World Journal of Gastroenterology

Volumn 20, Issue 16, 2014, Pages 4681-4691

  El Naghi, Suzan ^a,b   Abdel Ghaffar, Tawhida Y ^b,c   El Karaksy, Hanaa ^d   Abdel Aty, Elham F ^e   El Raziky, Mona S ^d   Allam, Aleef A ^e   Helmy, Heba ^d   El Araby, Hanaa A ^e   Behairy, Behairy E ^e   El Guindi, Mohamed A ^e   El Sebaie, Hatem ^e   Abdel Ghaffar, Aisha Y ^f   Ehsan, Nermin A ^g   El Hennawy, Ahmed M ^a   Sira, Mostafa M ^e  

^a NATIONAL HEPATOLOGY AND TROPICAL MEDICINE RESEARCH INSTITUTE   (Egypt)

^b Prof Ghaffar Charity Ctr for Liver   (Egypt)

^c AIN SHAMS UNIVERSITY   (Egypt)

^d CAIRO UNIVERSITY   (Egypt)

^e MENOUFIA UNIVERSITY   (Egypt)

^f AIN SHAMS UNIVERSITY   (Egypt)

^g MENOUFIA UNIVERSITY   (Egypt)

Author keywords

Children; Chronic hepatitis C; Hansenula polymorpha; Pegylated interferon; Response rate; Ribavirin; Treatment

Indexed keywords

ALANINE AMINOTRANSFERASE; ANTIVIRUS AGENT; ASPARTATE AMINOTRANSFERASE; PEGYLATED INTERFERON ALFA 2A; REIFERON RETARD; RIBAVIRIN; UNCLASSIFIED DRUG; ALPHA INTERFERON; BIOLOGICAL MARKER; MACROGOL DERIVATIVE; PEGINTERFERON ALPHA2A; RECOMBINANT PROTEIN; VIRUS RNA;

ADOLESCENT; ADULT; ANEMIA; ARTICLE; CHILD; CLINICAL ARTICLE; DISEASE ACTIVITY; DISEASE DURATION; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERANCE; EGYPT; FEMALE; FEVER; FIBROSIS; FLU LIKE SYNDROME; FOLLOW UP; HEPATITIS C; HUMAN; HUMAN TISSUE; HYPERTRANSAMINASEMIA; LIVER BIOPSY; MALE; NEUTROPENIA; POLYMERASE CHAIN REACTION; PREDICTIVE VALUE; PRESCHOOL CHILD; RELAPSE; RISK FACTOR; SCHOOL CHILD; SENSITIVITY AND SPECIFICITY; SEX DIFFERENCE; TREATMENT DURATION; TREATMENT RESPONSE; VIRUS LOAD; AGE; BIOSYNTHESIS; BLOOD; CLINICAL TRIAL; DRUG ADMINISTRATION; DRUG COMBINATION; DRUG EFFECTS; GENETICS; GROWTH, DEVELOPMENT AND AGING; HEPACIVIRUS; HEPATITIS C, CHRONIC; METABOLISM; MULTICENTER STUDY; ORAL DRUG ADMINISTRATION; PICHIA; RECURRENT DISEASE; REMISSION; SUBCUTANEOUS DRUG ADMINISTRATION; TERTIARY CARE CENTER; TIME; TREATMENT OUTCOME; YOUNG ADULT;

ADMINISTRATION, ORAL; ADOLESCENT; AGE FACTORS; ANTIVIRAL AGENTS; BIOLOGICAL MARKERS; CHILD; CHILD, PRESCHOOL; DRUG ADMINISTRATION SCHEDULE; DRUG THERAPY, COMBINATION; EGYPT; FEMALE; HEPACIVIRUS; HEPATITIS C, CHRONIC; HUMANS; INJECTIONS, SUBCUTANEOUS; INTERFERON-ALPHA; MALE; PICHIA; POLYETHYLENE GLYCOLS; RECOMBINANT PROTEINS; RECURRENCE; REMISSION INDUCTION; RIBAVIRIN; RNA, VIRAL; TERTIARY CARE CENTERS; TIME FACTORS; TREATMENT OUTCOME; VIRAL LOAD; YOUNG ADULT;

EID: 84899622393     PISSN: 10079327     EISSN: 22192840     Source Type: Journal    
DOI: 10.3748/wjg.v20.i16.4681     Document Type: Article

References (49)

1. Hoofnagle JH. Hepatitis C: the clinical spectrum of disease. Hepatology 1997; 26: 15S-20S [PMID: 9305658 DOI: 10.1002/ hep.510260703]
2. Webster DP, Klenerman P, Collier J, Jeffery KJ. Development of novel treatments for hepatitis C. Lancet Infect Dis 2009; 9: 108-117 [PMID: 19179226 DOI: 10.1016/ S1473-3099(09)70020-9]
3. Abdel-Wahab MF, Zakaria S, Kamel M, Abdel-Khaliq MK, Mabrouk MA, Salama H, Esmat G, Thomas DL, Strickland GT. High seroprevalence of hepatitis C infection among risk groups in Egypt. Am J Trop Med Hyg 1994; 51: 563-567 [PMID: 7527186]
4. Frank C, Mohamed MK, Strickland GT, Lavanchy D, Arthur RR, Magder LS, El Khoby T, Abdel-Wahab Y, Aly Ohn ES, Anwar W, Sallam I. The role of parenteral antischistosomal therapy in the spread of hepatitis C virus in Egypt. Lancet 2000; 355: 887-891 [PMID: 10752705 DOI: 10.1016/ S0140-6736(99)06527-7]
5. Kamal SM, Nasser IA. Hepatitis C genotype 4: What we know and what we don't yet know. Hepatology 2008; 47: 1371-1383 [PMID: 18240152 DOI: 10.1002/hep.22127]
6. El-Raziky MS, El-Hawary M, Esmat G, Abouzied AM, El- Koofy N, Mohsen N, Mansour S, Shaheen A, Abdel Hamid M, El-Karaksy H. Prevalence and risk factors of asymptomatic hepatitis C virus infection in Egyptian children. World J Gastroenterol 2007; 13: 1828-1832 [PMID: 17465475]
7. Busch MP, Glynn SA, Stramer SL, Strong DM, Caglioti S, Wright DJ, Pappalardo B, Kleinman SH. A new strategy for estimating risks of transfusion-transmitted viral infections based on rates of detection of recently infected donors. Transfusion 2005; 45: 254-264 [PMID: 15660836 DOI: 10.1111/ j.1537-2995.2004.04215.x]
8. Mack CL, Gonzalez-Peralta RP, Gupta N, Leung D, Narkewicz MR, Roberts EA, Rosenthal P, Schwarz KB. NASPGHAN practice guidelines: Diagnosis and management of hepatitis C infection in infants, children, and adolescents. J Pediatr Gastroenterol Nutr 2012; 54: 838-855 [PMID: 22487950 DOI: 10.1097/MPG.0b013e318258328d]
9. Jara P, Hierro L. Treatment of hepatitis C in children. Expert Rev Gastroenterol Hepatol 2010; 4: 51-61 [PMID: 20136589 DOI: 10.1586/egh.09.76]
10. Shebl FM, El-Kamary SS, Saleh DA, Abdel-Hamid M, Mikhail N, Allam A, El-Arabi H, Elhenawy I, El-Kafrawy S, El-Daly M, Selim S, El-Wahab AA, Mostafa M, Sharaf S, Hashem M, Heyward S, Stine OC, Magder LS, Stoszek S, Strickland GT. Prospective cohort study of mother-to-infant infection and clearance of hepatitis C in rural Egyptian villages. J Med Virol 2009; 81: 1024-1031 [PMID: 19382251 DOI: 10.1002/jmv.21480]
11. Jara P, Resti M, Hierro L, Giacchino R, Barbera C, Zancan L, Crivellaro C, Sokal E, Azzari C, Guido M, Bortolotti F. Chronic hepatitis C virus infection in childhood: clinical patterns and evolution in 224 white children. Clin Infect Dis 2003; 36: 275-280 [PMID: 12539067 DOI: 10.1086/345908]
12. Yee HS, Currie SL, Darling JM, Wright TL. Management and treatment of hepatitis C viral infection: recommendations from the Department of Veterans Affairs Hepatitis C Resource Center program and the National Hepatitis C Program office. Am J Gastroenterol 2006; 101: 2360-2378 [PMID: 17032203 DOI: 10.1111/j.1572-0241.2006.00754.x]
13. Kamal SM. Hepatitis C genotype 4 therapy: increasing options and improving outcomes. Liver Int 2009; 29 Suppl 1: 39-48 [PMID: 19207965]
14. Varghese R, Al-Khaldi J, Asker H, Fadili AA, Al Ali J, Hassan FA. Treatment of chronic hepatitis C genotype 4 with peginterferon alpha-2a plus ribavirin. Hepatogastroenterology 2009; 56: 218-222 [PMID: 19453061]
15. Buti M, Lurie Y, Zakharova NG, Blokhina NP, Horban A, Teuber G, Sarrazin C, Balciuniene L, Feinman SV, Faruqi R, Pedicone LD, Esteban R. Randomized trial of peginterferon alfa-2b and ribavirin for 48 or 72 weeks in patients with hepatitis C virus genotype 1 and slow virologic response. Hepatology 2010; 52: 1201-1207 [PMID: 20683847 DOI: 10.1002/ hep.23816]
16. Russo MW, Fried MW. Guidelines for stopping therapy in chronic hepatitis C. Curr Gastroenterol Rep 2004; 6: 17-21 [PMID: 14720449 DOI: 10.1007/s11894-004-0021-6]
17. Craxì A. Early virologic response with pegylated interferons. Dig Liver Dis 2004; 36 Suppl 3: S340-S343 [PMID: 15645664 DOI: 10.1016/S1590-8658(04)80003-3]
18. Sherman M, Shafran S, Burak K, Doucette K, Wong W, Girgrah N, Yoshida E, Renner E, Wong P, Deschênes M. Management of chronic hepatitis C: consensus guidelines. Can J Gastroenterol 2007; 21 Suppl C: 25C-34C [PMID: 17568824]
19. Drusano GL, Preston SL. A 48-week duration of therapy with pegylated interferon alpha 2b plus ribavirin may be too short to maximize long-term response among patients infected with genotype-1 hepatitis C virus. J Infect Dis 2004; 189: 964-970 [PMID: 14999598 DOI: 10.1086/382279]
20. Esmat G, Fattah SA. Evaluation of a novel pegylated interferon alpha-2a (Reiferon Retard®) in Egyptian patients with chronic hepatitis C - genotype 4. Dig Liver Disease Suppl 2009; 3: 17-19 [DOI: 10.1016/S1594-5804(09)60011-5]
21. Esmat G, Hadi G. A Novel PEG-IFN-alpha2A in Chronic HCV Genotype 4 Patients. J Interferon Cytokine Res 2007; 27: 691-712 [DOI: 10.1089/jir.2007.9981]
22. Shehab HM. Efficacy of Nitazoxanide in the Treatment of Chronic Hepatitis C Virus (HCV) Sponsors and Collaborators. In: ClinicalTrials.gov [Internet]. Egyptian Railway Hospital; Cairo University (EGY). [cited 2013 Dec 27]. Available from: URL: http://clinicaltrials.gov/show/NCT01276756 NLM Identifier: NCT01276756
23. Ghany MG, Strader DB, Thomas DL, Seeff LB. Diagnosis, management, and treatment of hepatitis C: an update. Hepatology 2009; 49: 1335-1374 [PMID: 19330875 DOI: 10.1002/ hep.22759]
24. Ishak K, Baptista A, Bianchi L, Callea F, De Groote J, Gudat F, Denk H, Desmet V, Korb G, MacSween RN. Histological grading and staging of chronic hepatitis. J Hepatol 1995; 22: 696-699 [PMID: 7560864 DOI: 10.1016/0168-8278(95)80226-6]
25. Esmat G, Metwally M, Zalata KR, Gadalla S, Abdel-Hamid M, Abouzied A, Shaheen AA, El-Raziky M, Khatab H, El- Kafrawy S, Mikhail N, Magder LS, Afdhal NH, Strickland GT. Evaluation of serum biomarkers of fibrosis and injury in Egyptian patients with chronic hepatitis C. J Hepatol 2007; 46: 620-627 [PMID: 17316875]
26. Giannattasio A, Spagnuolo MI, Sepe A, Valerio G, Vecchione R, Vegnente A, Iorio R. Is HCV infection associated with liver steatosis also in children? J Hepatol 2006; 45: 350-354 [PMID: 16750584 DOI: 10.1016/j.jhep.2006.03.010]
27. Afifi MT, El-Gohary A. Evaluation of the effi cacy and safety of pegylated interferon α2a 160 μg (reiferon retard) and ribavirin combination in chronic HCV genotype 4 patients (Poster Abstracts II). Proceedings of Asian Pacific Digestive Week; 2010 Sep 19-22; Kuala Lampur, Malaysia. J Gastroenterol Hepatol 2010; 25: A79-A176 [DOI: 10.1111/ j.1440-1746.2009.06464.x]
28. Amer M, El Sayed A, Afifi MMA, Awad SE. Response to Combination Therapy with a Hansenula-derived Pegylated- Iinterferon alpha-2-a and Ribavirin in Naive Egyptian Patients with Chronic Hepatitis C Genotype 4. Proceedings of 18th United European Gastroenterology Week; 2010 Oct 23-27; Barcelona, Spain, A321 P1064. Gut 2010; 59: A321
29. Taha AA, El-Ray A, El-Ghannam M, Mounir B. Efficacy and safety of a novel pegylated interferon alpha-2a in Egyptian patients with genotype 4 chronic hepatitis C. Can J Gastroenterol 2010; 24: 597-602 [PMID: 21037988]
30. Derbala M, Rizk N, Al-Kaabi S, Amer A, Shebl F, Al Marri A, Aigha I, Alyaesi D, Mohamed H, Aman H, Basem N. Adiponectin changes in HCV-Genotype 4: relation to liver histology and response to treatment. J Viral Hepat 2009; 16: 689-696 [PMID: 19486470 DOI: 10.1111/j.1365-2893.2009.01096.x]
31. Derbala MF, El Dweik NZ, Al Kaabi SR, Al-Marri AD, Pasic F, Bener AB, Shebl FM, Amer AM, Butt MT, Yakoob R, John A, Al Mohanadi M, Al Khinji MA. Viral kinetic of HCV genotype-4 during pegylated interferon alpha 2a: ribavirin therapy. J Viral Hepat 2008; 15: 591-599 [PMID: 18482284 DOI: 10.1111/j.1365-2893.2008.00988.x]
32. El Makhzangy H, Esmat G, Said M, Elraziky M, Shouman S, Refai R, Rekacewicz C, Gad RR, Vignier N, Abdel-Hamid M, Zalata K, Bedossa P, Pol S, Fontanet A, Mohamed MK. Response to pegylated interferon alfa-2a and ribavirin in chronic hepatitis C genotype 4. J Med Virol 2009; 81: 1576-1583 [PMID: 19626613 DOI: 10.1002/jmv.21570]
33. Kamal SM, El Kamary SS, Shardell MD, Hashem M, Ahmed IN, Muhammadi M, Sayed K, Moustafa A, Hakem SA, Ibrahiem A, Moniem M, Mansour H, Abdelaziz M. Pegylated interferon alpha-2b plus ribavirin in patients with genotype 4 chronic hepatitis C: The role of rapid and early virologic response. Hepatology 2007; 46: 1732-1740 [PMID: 17943989 DOI: 10.1002/hep.21917]
34. Derbala M, Amer A, Bener A, Lopez AC, Omar M, El Ghannam M. Pegylated interferon-alpha 2b-ribavirin combination in Egyptian patients with genotype 4 chronic hepatitis. J Viral Hepat 2005; 12: 380-385 [PMID: 15985008 DOI: 10.1111/j.1365-2893.2005.00604.x]
35. Wirth S, Ribes-Koninckx C, Calzado MA, Bortolotti F, Zancan L, Jara P, Shelton M, Kerkar N, Galoppo M, Pedreira A, Rodriguez-Baez N, Ciocca M, Lachaux A, Lacaille F, Lang T, Kullmer U, Huber WD, Gonzalez T, Pollack H, Alonso E, Broue P, Ramakrishna J, Neigut D, Valle-Segarra AD, Hunter B, Goodman Z, Xu CR, Zheng H, Noviello S, Sniukiene V, Brass C, Albrecht JK. High sustained virologic response rates in children with chronic hepatitis C receiving peginterferon alfa-2b plus ribavirin. J Hepatol 2010; 52: 501-507 [PMID: 20189674 DOI: 10.1016/j.jhep.2010.01.016]
36. Schwarz KB, Gonzalez-Peralta RP, Murray KF, Molleston JP, Haber BA, Jonas MM, Rosenthal P, Mohan P, Balistreri WF, Narkewicz MR, Smith L, Lobritto SJ, Rossi S, Valsamakis A, Goodman Z, Robuck PR, Barton BA. The combination of ribavirin and peginterferon is superior to peginterferon and placebo for children and adolescents with chronic hepatitis C. Gastroenterology 2011; 140: 450-458.e1 [PMID: 21036173 DOI: 10.1053/j.gastro.2010.10.047]
37. Al Ali J, Owayed S, Al-Qabandi W, Husain K, Hasan F. Pegylated interferon alfa-2b plus ribavirin for the treatment of chronic hepatitis C genotype 4 in adolescents. Ann Hepatol 2010; 9: 156-160 [PMID: 20526008]
38. Jara P, Hierro L, de la Vega A, Díaz C, Camarena C, Frauca E, Miños-Bartolo G, Díez-Dorado R, de Guevara CL, Larrauri J, Rueda M. Efficacy and safety of peginterferon-alpha2b and ribavirin combination therapy in children with chronic hepatitis C infection. Pediatr Infect Dis J 2008; 27: 142-148 [PMID: 18174875 DOI: 10.1097/INF.0b013e318159836c]
39. Pawłowska M, Pilarczyk M, Halota W. Virologic response to treatment with Pegylated Interferon alfa-2b and Ribavirin for chronic hepatitis C in children. Med Sci Monit 2010; 16: CR616-CR621 [PMID: 21119580]
40. Sokal EM, Bourgois A, Stéphenne X, Silveira T, Porta G, Gardovska D, Fischler B, Kelly D. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection in children and adolescents. J Hepatol 2010; 52: 827-831 [PMID: 20400194 DOI: 10.1016/j.jhep.2010.01.028]
41. Wirth S, Pieper-Boustani H, Lang T, Ballauff A, Kullmer U, Gerner P, Wintermeyer P, Jenke A. Peginterferon alfa- 2b plus ribavirin treatment in children and adolescents with chronic hepatitis C. Hepatology 2005; 41: 1013-1018 [PMID: 15793840 DOI: 10.1002/hep.20661]
42. Zhang HF, Yang XJ, Zhu SS, Dong Y, Chen DW, Jia WZ, Xu ZQ, Mao YL, Tang HM. [An open-label pilot study evaluating the efficacy and safety of peginterferon alfa-2a combined with ribavirin in children with chronic hepatitis C]. Zhonghua Shi Yan He Lin Chuang Bing Du Xue Zazhi 2005; 19: 185-187 [PMID: 16027794]
43. Druyts E, Thorlund K, Wu P, Kanters S, Yaya S, Cooper CL, Mills EJ. Efficacy and safety of pegylated interferon alfa-2a or alfa-2b plus ribavirin for the treatment of chronic hepatitis C in children and adolescents: a systematic review and meta-analysis. Clin Infect Dis 2013; 56: 961-967 [PMID: 23243171 DOI: 10.1093/cid/cis1031]
44. Gerner P, Hilbich J, Wenzl TG, Behrens R, Walther F, Kliemann G, Enninger A, Wirth S. Re-treatment of children with chronic hepatitis C who did not respond to interferonalpha treatment. J Pediatr Gastroenterol Nutr 2010; 51: 187-190 [PMID: 20512050 DOI: 10.1097/MPG.0b013e3181d9c7f6]
45. Mangia A, Minerva N, Bacca D, Cozzolongo R, Ricci GL, Carretta V, Vinelli F, Scotto G, Montalto G, Romano M, Cristofaro G, Mottola L, Spirito F, Andriulli A. Individualized treatment duration for hepatitis C genotype 1 patients: A randomized controlled trial. Hepatology 2008; 47: 43-50 [PMID: 18069698 DOI: 10.1002/hep.22061]
46. Vuillermoz I, Khattab E, Sablon E, Ottevaere I, Durantel D, Vieux C, Trepo C, Zoulim F. Genetic variability of hepatitis C virus in chronically infected patients with viral breakthrough during interferon-ribavirin therapy. J Med Virol 2004; 74: 41-53 [PMID: 15258967 DOI: 10.1002/jmv.20144]
47. Zeuzem S, Andreone P, Pol S, Lawitz E, Diago M, Roberts S, Focaccia R, Younossi Z, Foster GR, Horban A, Ferenci P, Nevens F, Müllhaupt B, Pockros P, Terg R, Shouval D, van Hoek B, Weiland O, Van Heeswijk R, De Meyer S, Luo D, Boogaerts G, Polo R, Picchio G, Beumont M. Telaprevir for retreatment of HCV infection. N Engl J Med 2011; 364: 2417-2428 [PMID: 21696308 DOI: 10.1056/NEJMoa1013086]
48. Chayama K, Takahashi S, Toyota J, Karino Y, Ikeda K, Ishikawa H, Watanabe H, McPhee F, Hughes E, Kumada H. Dual therapy with the nonstructural protein 5A inhibitor, daclatasvir, and the nonstructural protein 3 protease inhibitor, asunaprevir, in hepatitis C virus genotype 1binfected null responders. Hepatology 2012; 55: 742-748 [PMID: 21987462 DOI: 10.1002/hep.24724]
49. Porto AF, Tormey L, Lim JK. Management of chronic hepatitis C infection in children. Curr Opin Pediatr 2012; 24: 113-120 [PMID: 22157364 DOI: 10.1097/MOP.0b013e32834eb73f]